Benjamin Besse, MD, PhD, shares AE management strategies for amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.
Benjamin Besse, MD, PhD
Advertisement
Benjamin Besse, MD, PhD, is the director of Clinical research at Gustave Roussy.
Articles by Benjamin Besse, MD, PhD
Advertisement
Latest Updated Articles
Safety Management With Amivantamab Plus Lazertinib in NSCLCPublished: September 11th 2025 | Updated:
Advertisement
Advertisement
